John Glover, LCSW in Mc Farland, WI - Social Worker

John Glover, LCSW is a Social Worker - Clinical based in Mc Farland, Wisconsin. John Glover is licensed to practice in Wisconsin (license number 872122) and his current practice location is 5708 Curtis St, Mc Farland, Wisconsin. He can be reached at his office (for appointments etc.) via phone at (608) 509-3553.

NPI number for John Glover is 1740256999 and his current mailing address is 5708 Curtis St, Mc Farland, Wisconsin. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1740256999.

Contact Information

	John Glover, LCSW
	5708 Curtis St, Mc Farland, WI 53558-9605
	(608) 509-3553
	Not Available

Healthcare Provider's Profile

Full Name	John Glover
Gender	Male
Speciality	Social Worker - Clinical
Location	5708 Curtis St, Mc Farland, Wisconsin
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1740256999
Provider Enumeration Date: 02/27/2006
Last Update Date: 10/28/2016

Medical Identifiers

Medical identifiers for John Glover such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1740256999	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1041C0700X	Social Worker - Clinical	872122 (Wisconsin)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. John Glover is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
John Glover, LCSW 5708 Curtis St, Mc Farland, WI 53558-9605 Ph: () -	John Glover, LCSW 5708 Curtis St, Mc Farland, WI 53558-9605 Ph: (608) 509-3553

News Archive

G-CSF therapy does not induce chromosomal instability in healthy stem cell donors

According to a study published in Blood, the Journal of the American Society of Hematology (ASH), researchers have reported that administration of granulocyte colony-stimulating factor (G-CSF), a drug that releases stem cells from the bone marrow into the blood, is unlikely to put healthy stem cell donors at risk for later development of abnormalities involving loss or gains of chromosomes that have been linked to hematologic disorders such as myelodysplastic syndromes (MDS) and acute myeloid leukemia.

Patients with sickle cell disease may require higher, frequent doses of morphine

Frequent episodes of severe pain occur in patients with sickle cell disease (SCD) and require treatment with potent opioid medications. A new study published in The Journal of Pain reports that SCD patients clear morphine from their blood stream quickly and, therefore, require high doses to achieve optimal analgesia.

Identifying, preventing and treating drug-induced arrhythmias

Health care professionals should become more familiar with medications that cause irregular heart rhythms called arrhythmias, according to "Drug- Induced Arrhythmias," a new scientific statement from the American Heart Association, published today in the Association's flagship journal Circulation.

Asterand subsidiary BioSeek signs agreement with Amylin

Asterand plc, a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery, today announces that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a one-year collaboration agreement with Amylin Pharmaceuticals, Inc.

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting about 7 million people in Europe. It is a progressive chronic disease in which episodes become more frequent and long-lasting over time. Conventional anti-arrhythmic therapy aims at halting progression and reducing symptoms, but the use of most anti-arrhythmic drugs is compromised by severe side effects, such as pro-arrhythmia or extra-cardiac organ toxicity.

John Glover, LCSW - Clinical Social Worker in Mc Farland, WI